Contraindicated (1)bortezomib will improve the amount or effect of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or moderate CYP2C19 inhibitors may possibly maximize mavacamten systemic publicity, leading to coronary heart failure as a result of systolic dysfunction. fluconazole will raise the stage or outcome of bortezomib by influencing https://fosaprepitantdimeglumine22098.blogpostie.com/48895272/ritobegron-hcl-an-overview